These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 4895455)

  • 21. Clofibrate in perspective.
    N Engl J Med; 1968 Oct; 279(16):885-6. PubMed ID: 5677725
    [No Abstract]   [Full Text] [Related]  

  • 22. [Changes of the coefficient of peripheral utilization of glucose after venous administration, in hypercholesteremic subjects, after treatment with an antidyslipidemic agent].
    Pasini P
    G Gerontol; 1969 Aug; 17(8):808-16. PubMed ID: 5371744
    [No Abstract]   [Full Text] [Related]  

  • 23. [Effect of clofibrate on serum lipids in atherosclerosis].
    Gietz E
    Med Klin; 1967 Mar; 62(9):336-8 passim. PubMed ID: 5593571
    [No Abstract]   [Full Text] [Related]  

  • 24. Hypolipidemic agents--newly approved.
    Duncan GG
    Pa Med; 1967 Aug; 70(8):75-6. PubMed ID: 6073724
    [No Abstract]   [Full Text] [Related]  

  • 25. [Effects of clofibrate in the treatment of hyperlipidemia. (Apropos of 61 cases)].
    Warembourg H; Jaillard J
    Rev Atheroscler (Paris); 1966; 8(1):53-5. PubMed ID: 5961028
    [No Abstract]   [Full Text] [Related]  

  • 26. [The therapeutic use of CPIB in pathological increase of the lipid constituents of the blood].
    Cloarec M; Cottet J; Etienne J; Loeper J
    Sem Ther; 1965 Nov; 41(9):499-500. PubMed ID: 5877602
    [No Abstract]   [Full Text] [Related]  

  • 27. [Influence of beta-benzabutyramide on the blood lipids and on the thrombodensitogram].
    Ferri F; Regazzini A; Pedini G
    G Gerontol; 1970 Mar; 18(3):203-18. PubMed ID: 5473222
    [No Abstract]   [Full Text] [Related]  

  • 28. [Experience with 110 medium-length therapeutic trials of ethyl chlorophenoxyisobutyrate with or without androsterone in various types of idiopathic hyperlipidemia].
    De Gennes JL; Maunand B; Salmon D; Laudat P; Truffert J
    Rev Atheroscler (Paris); 1966; 8(1):27-52. PubMed ID: 5961027
    [No Abstract]   [Full Text] [Related]  

  • 29. [Prolonged use of atromid in patients with coronary arteriosclerosis].
    Zadionchenko VS
    Kardiologiia; 1967 Oct; 7(10):32-5. PubMed ID: 5607197
    [No Abstract]   [Full Text] [Related]  

  • 30. Familial hypercholesterolaemic xanthomatosis and coronary heart disease in a ten-year-old girl.
    Miettinen M
    Ann Paediatr Fenn; 1967; 13(1):35-8. PubMed ID: 6079714
    [No Abstract]   [Full Text] [Related]  

  • 31. Some clinical potentials of chlorophenoxyisobutyrate (clofibrate) therapy (hyperlipidemia--angina pectoris--blood sludging-diabetic neuropathy).
    Duncan GG; Elliott FA; Duncan TG; Schatanoff J
    Metabolism; 1968 May; 17(5):457-73. PubMed ID: 5648211
    [No Abstract]   [Full Text] [Related]  

  • 32. [Action of ethyl chlorophenoxyisobutyrate on several types of hyperlipidemia].
    Beaumont V; Swynghedauw B; Beaumont JL; Himbert J
    Rev Atheroscler (Paris); 1966; 8(1):12-20. PubMed ID: 5961026
    [No Abstract]   [Full Text] [Related]  

  • 33. [Medical treatment of hyperlipemia. Indications and modern preparations].
    Frey H
    Tidsskr Nor Laegeforen; 1968 Jan; 88(2):6-8. PubMed ID: 5663311
    [No Abstract]   [Full Text] [Related]  

  • 34. [Action of ethyl chlorophenoxyisobutyrate (CPIB) on blood lipids].
    Giannini SD; da Silva WN; Luthold WW; Coelho LT; Bitelli T
    Rev Bras Med; 1965 Nov; 22(11):702-7. PubMed ID: 5892979
    [No Abstract]   [Full Text] [Related]  

  • 35. [Action mechanism and clinical success of Regelan (Clofibrate)].
    Fitzgerald JD
    Wien Klin Wochenschr; 1967 Sep; 79(39):716-20. PubMed ID: 5595437
    [No Abstract]   [Full Text] [Related]  

  • 36. [The effect of Atromid treatment of patients with essential hyperlipidemia and xanthomatosis].
    Baranova LV
    Ter Arkh; 1967 Jul; 39(7):61-3. PubMed ID: 5610932
    [No Abstract]   [Full Text] [Related]  

  • 37. [The effect of retabolyl on the lipid and protein metabolism of coronary atherosclerosis patients].
    Savenkov PM; Segal' RG
    Kardiologiia; 1969 Jul; 9(7):95-100. PubMed ID: 5372695
    [No Abstract]   [Full Text] [Related]  

  • 38. Atromid-S for the reduction of plasma lipids.
    Med Lett Drugs Ther; 1967 Jun; 9(12):45-7. PubMed ID: 6037633
    [No Abstract]   [Full Text] [Related]  

  • 39. [Abnormal lipid metabolism and coronary insufficiency].
    Murakami M; Sekimoto H; Tanaka I; Seo M; Takegoshi T
    Saishin Igaku; 1970 Jan; 25(1):101-9. PubMed ID: 5450347
    [No Abstract]   [Full Text] [Related]  

  • 40. [Aggregation and adhesiveness of blood platelets in the physiopathology and prevention of thrombophilic states. Prospects and results of experimental and clinical research].
    De Nicola P; Gibelli A; Frandoli G; Giarola P; Turazza G
    G Gerontol; 1966 Oct; 14(10):941-51. PubMed ID: 5993790
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.